How a Dutch Startup Is Using AI to Tackle a Global Hearing Crisis

Jan de Vries · 2026-08-28

Okay, let's talk about something that's happening in Europe right now that's quietly pretty exciting. It's not just another funding headline. It's about a company that's trying to solve a massive, quiet problem affecting billions of people. And they just got a significant boost to do it. A startup called Clementine, based in Maastricht in the Netherlands, just secured $2 million in Seed funding. Their mission? To fundamentally change how people with hearing loss get help. They've built an AI-powered platform specifically for the hearing care industry, and it's designed to do one crucial thing: turn potential patients who are hesitant into patients who are ready for care. Think about that for a second. Hearing loss is incredibly common, but the path to getting help is often full of delays and stigma. ### The Backing and the Vision This seed round was led by Healthy.Capital, an Amsterdam-based investor focused on early-stage health tech. They've backed other promising companies like Pharmi and OpenUp. Douwe Jippes, their managing partner, put it perfectly: "Clementine combines deep domain expertise with a clear AI platform strategy that can scale globally. We believe this approach will fundamentally change how people with hearing disability engage with hearing healthcare." That's the key. It's not just about the technology; it's about understanding the human barriers. Founded in 2024 by CEO Vince van de Weijer, Clementine (or ClementineAI) calls itself the world's first AI hearing activation platform. ### Meet Matthew: The AI Agent Changing the Conversation So, what does this platform actually do? It all centers on an AI agent named Matthew. Imagine a prospective patient visits a clinic's website at 2 AM, filled with questions but maybe too self-conscious to call. Matthew is there. - He can answer questions 24/7, no judgment, no waiting list. - He educates users, helping them overcome both emotional and practical hurdles. - He gently guides them toward the appropriate next steps for care. For clinics, this is a game-changer. Staff are often overwhelmed. "Clinics don't need more leads; they need better conversations at the right moment," says van de Weijer. Matthew handles those initial conversations, eliminates administrative grunt work, and—most importantly—translates inquiries into actual bookings. ### The Scale of the Problem and the Opportunity Here's the staggering part. Clementine points out that hearing loss affects roughly 1.5 billion people worldwide. Yet, nearly 80% of those people never seek treatment. And for the ones who do? They typically wait over eight years before doing anything about it. Eight years. That's a lifetime of missed conversations and fading connections. Clementine's approach is to pair AI with behavioral science. The goal is to offer a judgment-free, always-available starting point. It's about meeting people where they are, long before they're ready to physically walk into a clinic. ### What's Next for Clementine? The timing of this funding is interesting. It comes just months after Clementine expanded into North America through a partnership with Zoolstra, a marketing agency that works with hearing clinics across the United States and Canada. That's a big move. So, what will this $2 million seed round be used for? The company plans to deepen its AI capabilities, making Matthew even more intuitive and helpful. They also aim to expand their network of partnerships, not just with hearing clinics, but also with optical retailers and other healthcare organizations where hearing care conversations can naturally begin. This isn't just a story about a startup raising money. It's a story about applying smart, empathetic technology to one of the most overlooked chronic health issues in the world. By tackling the initial barrier of conversation, Clementine is trying to unlock care for millions. And now, with fresh capital and a clear vision, they're scaling up to see if their AI agent can truly help the world listen.